Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

44.80
+0.55001.24%
Post-market: 44.50-0.3000-0.67%16:16 EST
Volume:5.71M
Turnover:256.27M
Market Cap:26.13B
PE:25.58
High:45.27
Open:44.24
Low:44.05
Close:44.25
52wk High:45.27
52wk Low:29.66
Shares:583.17M
Float Shares:379.85M
Volume Ratio:1.34
T/O Rate:1.50%
Dividend:0.87
Dividend Rate:1.94%
EPS(TTM):1.75
EPS(LYR):1.92
ROE:13.11%
ROA:5.22%
PB:4.07
PE(LYR):23.37

Loading ...

Royalty Pharma (RPRX) Margin Reset To 32.6% Tests Bullish Profitability Narratives

Simply Wall St.
·
56 mins ago

Royalty Pharma price target raised to $51 from $45 at Goldman Sachs

TIPRANKS
·
Yesterday

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
Yesterday

Stock Track | Royalty Pharma Plunges 6.31% in Pre-Market After Q4 Sales Miss Estimates

Stock Track
·
Feb 11

Royalty Pharma Q4 adjusted EBITDA beats analyst expectations

Reuters
·
Feb 11

Earnings Flash (RPRX) Royalty Pharma Posts Q4 Revenue $622M

MT Newswires Live
·
Feb 11

Royalty Pharma Q4 net income attributable to shareholders USD 214 million

Reuters
·
Feb 11

Royalty Pharma Reports Q4 and Full Year 2025 Results

THOMSON REUTERS
·
Feb 11

Royalty Pharma: Full Year 2026 Guidance: Portfolio Receipts Expected to Be $3,275 Million to $3,425 Million

THOMSON REUTERS
·
Feb 11

Royalty Pharma Q4 Adjusted Ebitda USD 816 Million VS. Ibes Estimate USD 723.3 Million

THOMSON REUTERS
·
Feb 11

Royalty Pharma CFO Terrance P. Coyne Reports Disposal of Common Shares

Reuters
·
Feb 05

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Feb 03

Royalty Pharma Shares Rise After UBS Upgrade

MT Newswires Live
·
Jan 31

UBS Upgrades Royalty Pharma to Buy From Neutral, Adjusts Price Target to $49 From $38

MT Newswires Live
·
Jan 31

Assessing Royalty Pharma (RPRX) Valuation After Teva Autoimmune Funding Partnership Attracts Fresh Attention

Simply Wall St.
·
Jan 29

Royalty Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
Jan 27

Royalty Pharma EVP Marshall Urist Reports Disposal of Common Shares

Reuters
·
Jan 27

EVP Marshall Urist Reports Disposal of Royalty Pharma plc Common Shares

Reuters
·
Jan 21

Royalty Pharma plc to Announce Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Jan 21

Royalty Pharma EVP Marshall Urist Reports Sale of Common Shares

Reuters
·
Jan 14